Topics

The Hypersomnia Foundation, Inc. Company Profile

04:39 EST 27th January 2020 | BioPortfolio

The Hypersomnia Foundation, Inc. strives to improve the lives of people with idiopathic hypersomnia and related disorders by advocating on their behalf, providing support and information, raising awareness and aiding research. For more: http://www.hypersomniafoundation.org/ and follow us on Twitter and Facebook. Let’s Get #BeyondSleepy #HFconf


News Articles [400 Associated News Articles listed on BioPortfolio]

Dr. Caroline Maness of Emory University Receives Hypersomnia Foundation Research Award

The HYPERSOMNIA FOUNDATION, a leading nonprofit patient advocacy group dedicated to improving the lives of people with idiopathic hypersomnia and other rare sleep disorders, is pleased to announce th...

2019 Hypersomnia Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Hypersomnia Clinical Trials Study provides complete list of trials completed, ongoing and planned for Hypersomnia. It presents indepth analysis of Hypersomnia cl...

2019 Hypersomnia Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1583

The global clinical trial report 2019 Hypersomnia Clinical Trials Study provides complete list of trials completed, ongoing and planned for Hypersomnia. It presents indepth analysis of Hypersomnia cl...

Hypersomnia Foundation Hosting Forum in Seattle Connecting Sleep Disorder Patients With Researchers and Patient Advocates

The HYPERSOMNIA FOUNDATION (HF), a leading nonprofit patient advocacy group dedicated to improving the lives of people with idiopathic hypersomnia and other rare sleep disorders, will be holding a

New Leader To Take Over At Bill & Melinda Gates Foundation, The Country’s Largest Private Foundation

Mark Suzman, the foundation’s chief strategy officer, will replace CEO Susan Desmond-Hellman. Suzman will be the fourth CEO of the Gates Foundation.

Hypersomnia Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975

FirstView Market Insight Hypersomnia Market Review, Epidemiology And Market Forecast 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market i...

Hypersomnia Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $3080

FirstView Market Insight Hypersomnia Market Review, Epidemiology And Market Forecast 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market i...

Hypersomnia Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2380

FirstView Market Insight Hypersomnia Market Review, Epidemiology And Market Forecast 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market i...

Drugs and Medications [31 Associated Drugs and Medications listed on BioPortfolio]

No7 protect and perfect foundation sunscreen broad spectrum spf 15 calico [boots retail usa inc]

NA

Meloxicam [kaiser foundation hospitals]

These highlights do not include all the information needed to use MELOXICAM TABLETS USP. safely and effectively. See full prescribing information for MELOXICAM TABLETS USP. MELOXICAM Tablets USP, for ...

Benzonatate [kaiser foundation hospitals]

Benzonatate Capsules, USP 100 mg

Misoprostol [kaiser foundation hospitals]

Misoprostol Tablets 8204001/0613 Rx Only

Oxygen [cornerstone mecial services - midwest, llc]

Oxygen

PubMed Articles [200 Associated PubMed Articles listed on BioPortfolio]

Development and validation of the Hypersomnia Severity Index (HSI): A measure to assess hypersomnia severity and impairment in psychiatric disorders.

Hypersomnia is common in psychiatric disorders, yet there are few self-report measures that adequately characterize this sleep disturbance. The objective of this study was to validate the Hypersomnia ...

Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders.

The identification of AQP4-IgG, a specific and pathogenic antibody of NMO/SD has led to a broadening of the clinical spectrum of manifestations of NMO/SD including the presence of encephalic symptoms....

The Epidemiology of Patient-Reported Hypersomnia in Persons With Advanced Age.

To examine the epidemiology and key demographic and clinical correlates of patient-reported hypersomnia in persons with advanced age.

Florence Nightingale Foundation: what next?

Newly appointed Chair of the Florence Nightingale Foundation, shares her vision for the Foundation.

A Helmholtz resonator on elastic foundation for measurement of the elastic coefficient of human skin.

A new sensing mechanism is proposed for the measurement of elasticity of human skin by utilizing Helmholtz resonator with a flexible membrane mounted at the bottom and putting on an elastic foundation...

Clinical Trials [374 Associated Clinical Trials listed on BioPortfolio]

Psychosocial Adjunctive Treatment for Hypersomnia (PATH)

Current pharmacological treatments for chronic hypersomnia (narcolepsy, idiopathic hypersomnia) can effectively reduce excessive daytime sleepiness but a high proportion of patients experi...

A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic Hypersomnia

The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to participants with idiopathic hypersomnia (IH).

Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia (Actisom dépistage)

7 to 14 days actimetry recording in order to exclude sleep deprivation just before hospitalisation for differential diagnosis of hypersomnia

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

For diseases that cause excessive daytime sleepiness (such as narcolepsy and idiopathic hypersomnia), there are several medications that can be used to treat sleepiness. However, it can be...

Companies [1445 Associated Companies listed on BioPortfolio]

The Hypersomnia Foundation, Inc.

The Hypersomnia Foundation, Inc. strives to improve the lives of people with idiopathic hypersomnia and related disorders by advocating on their behalf, providing support and info...

Hypersomnia Foundation

AVA Foundation

The AVA Foundation is a 501(c)(3) educational and research foundation dedicated to saving lives through promoting risk-free vascular access and evidence-based clinical practice. T...

COSHAR Foundation

The COSHAR Foundation is a 501( c )3 organization dedicated to "Impacting the Health of the World, One Community at a Time." The COSHAR Foundation's NHMN includes more than 14,000 churches and 220 co...

The NASCAR Foundation

The National Association for Stock Car Auto Racing, Inc., (NASCAR) launched The NASCAR Foundation in January 2006. The Foundation is a 501(c)(3) non-profit entity that embodies the compassion of the N...

More Information about "The Hypersomnia Foundation, Inc." on BioPortfolio

We have published hundreds of The Hypersomnia Foundation, Inc. news stories on BioPortfolio along with dozens of The Hypersomnia Foundation, Inc. Clinical Trials and PubMed Articles about The Hypersomnia Foundation, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Hypersomnia Foundation, Inc. Companies in our database. You can also find out about relevant The Hypersomnia Foundation, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record